MF-1, neutralizing monoclonal antibody for VEGFR1/Flt-1, could block the interaction of ligands with VEGFR1, subsequently suppressing tumor cell proliferation and angiogenesis, and leading to tumor cell apoptosis.[42, 43] In this study, MF-1 treatment reversed the anti-oxidant effects of PlGF in cultured cardiomyocytes. Here, FLT1 is linked to neoplasm.